Paris - Delayed Quote EUR

Advicenne S.A. (ALDVI.PA)

2.5200

+0.0300

(+1.20%)

At close: June 7 at 5:35 PM GMT+2

FDA Grants Orphan Drug Designation to ADV7103 for the Treatment of Cystinuria.

PARIS, March 25, 2024--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announced that its proprietary drug ADV7103 has been granted Orphan Drug Designation (ODD) status for the treatment of cystinuria. This designation was issued by the US Food and Drug Administration (US FDA). ADV7103 is one of the few drugs t

Business Wire 2 months ago

ALDVI.PA
+1.20%
Advicenne Launches a Capital Increase With Preferential Subscription Rights ("PSR") to Accelerate Growth in Europe and Optimize Clinical Development of ADV7103

PARIS, September 11, 2023--Regulatory News: This press release must not be distributed directly or indirectly in the United States, Canada, Australia, or Japan.

Business Wire 8 months ago

ALDVI.PA
+1.20%

Performance Overview

Return	ALDVI.PA	CAC 40
YTD	-5.26%	+6.08%
1-Year	-40.18%	+11.00%
3-Year	-71.13%	+22.81%